Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 11 of 11 results for methylprednisolone

  1. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    Question Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with...

  2. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  3. Multiple sclerosis (QS108)

    This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.

  4. Venetoclax for treating chronic lymphocytic leukaemia (TA796)

    Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.

  5. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

  6. Crohn's disease: management (NG129)

    This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.

  7. Spinal injury: assessment and initial management (NG41)

    This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease. It aims to reduce death and disability by improving the quality of emergency and urgent care.

  8. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

  9. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

  10. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

  11. Research recommendations

    CG186/2 | Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with...